Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women - The Women's Health Initiative Memory Study: A Randomized Controlled Trial

JAMA

Volumn 289, Issue 20, 2003, Pages 2663-2672

  Rapp, Stephen R ^a   Espeland, Mark A ^a   Shumaker, Sally A ^a   Henderson, Victor W ^b   Brunner, Robert L ^c   Manson, JoAnn E ^d   Gass, Margery L S ^e   Stefanick, Marcia L ^f   Lane, Dorothy S ^g   Hays, Jennifer ^h   Johnson, Karen C ⁱ   Coker, Laura H ^a   Dailey, Maggie ^a   Bowen, Deborah ^j  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MENSTRUAL CYCLE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; AGED; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; RISK;

AGED; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; PROGESTERONE CONGENERS; RISK;

EID: 0038724280     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.20.2663     Document Type: Article

References (58)

1. Schaie KW. The course of adult intellectual development. Am Psychol. 1994;49:304-313.
2. Barker A, Jones R, Jennison C. A prevalence study of age-associated memory impairment. Br J Psychiatry. 1995;167:642-648.
3. Coria F, Gomez de Caso JA, Minguez L, Rodriguez-Artalejo F, Claveria LE. Prevalence of age-associated memory impairment and dementia in a rural community. J Neurol Neurosurg Psychiatry. 1993;56:973-976.
4. Larrabee GJ, Crook TH III. Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6:95-104.
5. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol. 2002;23:41-100.
6. Toran-Allerand CD. Organotypic culture of the developing cerebral cortex and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology. 1991;16:7-24.
7. Foy MR, Henderson VW, Berger TW, Thompson RF. Estrogen and neural plasticity. Curr Dir Psychol Sci. 2000;9:148-152.
8. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836-1844.
9. Osterlund MK, Grandien K, Keller E, Hurd YL. The human brain has distinct regional expression patterns of estrogen receptor alpha mRNA isoforms derived from alternative promoters. J Neurochem. 2000; 75:1390-1397.
10. Henderson VW. Hormone Therapy and the Brain: A Clinical Perspective on the Role of Estrogen. New York, NY: Parthenon Publishing; 2000.
11. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004-1007.
12. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women. In: The Cochrane Database of Systematic Reviews. Oxford, England: Update Software; 2002:CD003122.
13. Holst J, Backstrom T, Hammarback S, von Schoultz B. Progestogen addition during oestrogen replacement therapy-effects on vasomotor symptoms and mood. Maturitas. 1989;11:13-20.
14. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001;158:227-233.
15. Phillips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.
16. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
17. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.
18. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000;21:373-383.
19. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998;34:171-182.
20. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;10.1056/NEJMoa030311.
21. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
22. Polo-Kantola P, Portin R, Polo O. The effect of short-term estrogen replacement therapy on cognition: a randomized double-blind, cross-over trial in postmenopausal women. Obstet Gynecol. 1998;91: 459-466.
23. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas. 2001;38:137-146.
24. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288: 49-57.
25. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279: 688-695.
26. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
27. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19:604-621.
28. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
29. Shumaker SA, Legault C, Rapp SR, et al, for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
30. Teng EL, Chui HC. The 3MSE (3MS) examination. J Clin Psychiatry. 1987;48:314-318.
31. Teng EL, Chui H, Gong A. Comparisons between the Mini-Mental State Exam (MMSE) and its modified version - the 3MS test. In: Psychogeriatrics: Biomedical and Social Advances. Tokyo, Japan: Excerpta Medica; 1990:189-192.
32. Bravo G, Hebert R. Reliability of the Modified Mini-Mental State examination in the context of a two-phase community prevalence study. Neuroepidemiology. 1997;16:141-148.
33. Tombaugh TN, McDowell I, Kristjansson B, Hubley AM. Mini-Mental State examination (MMSE) and the modified MMSE (3MS): a psychometric comparison and normative data. Psychol Assess. 1996;8:48-59.
34. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini-Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997;50:377-383.
35. Nadler JD, Relkin NR, Cohen MS, Hodder RA, Reingold J, Plum F. Mental status testing in the elderly nursing home population. J Geriatr Psychiatry Neurol. 1995;8:177-183.
36. Bland RC, Newman SC. Mild dementia or cognitive impairment: the 3MSE examination (3MS) as a screen for dementia. Can J Psychiatry. 2001;46:506-510.
37. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-1796.
38. Kuller LH, Lopez OL, Newman A, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:13-22.
39. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
40. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 1996.
41. Murray DM, Hannan PJ, Wolfinger RD, Baker WL, Dwyer JH. Analysis of data from group-randomized trials with repeat observations on the same groups. Stat Med. 1998;17:1581-1600.
42. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
43. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89: 484-490.
44. Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51:535-541.
45. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res. 2002;57:357-384.
46. Brinton RD, Chen S, Montoya M, et al. The Women's Health Initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol Aging. 2000;21:475-496.
47. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology. 1997;49:1491-1497.
48. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology. 2001;57:2210-2216.
49. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc. 1999; 47:518-523.
50. Rice MM, Graves AB, McCurry SM, et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch Intern Med. 2000;160:1641-1649.
51. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485-512.
52. Morris JC, Heyman A, Mohs RC, et al. Consortium to Establish a Registry for Alzheimer's Disease (CERAD), Part I: clinical and neuropsychological assessmentof Alzheimer's disease. Neurology. 1989;39:1159-1165.
53. McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev. 1995;5:203-221.
54. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med. 2001;344:1207-1213.
55. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201-210.
56. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100:717-722.
57. Vermeer SE, Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
58. Henderson VW, Dudley EC, Gutherie JR, Burger HG, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology. 2003;60:1369-1371.